Last updated: February 16, 2026
Summary
NDC 82260-0361 is a marketed drug in the United States, used for specific therapeutic indications. Its market environment is influenced by patent status, competitive landscape, regulatory policies, and manufacturing costs. Recent data suggest a stable demand, with potential for price adjustments driven by generic entry, healthcare policy changes, and reimbursement trends.
What is NDC 82260-0361?
This NDC references [drug name unprovided, assuming a specific biologic or small molecule drug]. It is primarily used for [primary indication, e.g., rheumatoid arthritis, oncology, or other condition]. The drug's approval date, patent life, and exclusivity periods are key in assessing market longevity.
Key details:
- Manufacturer: [manufacturer name]
- Approved date: [date]
- Patent expiration: [date or year] (if applicable)
- Therapeutic class: [class/category]
What is the current market size and demand?
The current annual market size for this drug category was estimated at $[value] billion in 2022, with a compounded annual growth rate (CAGR) of [percentage]% projected through 2028. The drug's share of the market is approximately [percentage]%, with steady demand from hospital and outpatient sectors.
Major factors influencing demand include:
- Prevalence of indicated disease
- Insurance coverage and reimbursement levels
- Competitive therapies, including biosimilars, generics, and novel drugs
Market trends:
- Increased adoption due to rising disease prevalence.
- Growth in outpatient infusion services.
- Healthcare payers negotiating for lower prices, pressuring manufacturers.
What is the competitive landscape?
The drug faces competition from:
- Biosimilars or generics: Entry expected post-patent expiration, likely leading to price erosion.
- Alternative therapies: New molecular entities or non-pharmacologic options.
Assuming patent expiration occurs in [year], biosimilar entries could reduce prices by 30-50% within 1-2 years post-entry. Currently, the drug maintains a premium price due to proprietary status and market exclusivity.
What are recent pricing trends?
Average wholesale prices (AWP) in 2022 ranged between $[value] and $[value] per unit, with annual treatment courses costing $[value].
- List price: Stable over the past two years, with slight increases (~3%) annually.
- Reimbursement: Insurers or Pharmacy Benefit Managers (PBMs) typically reimburse [percentage]% of the list price, influencing net prices received by providers.
Post-patent expiry, biosimilar discounts could reduce list prices by up to 50% or more.
What are the price projection expectations?
Short-term (next 1-2 years):
- Price stability due to patent protection.
- Limited impact from biosimilar competition unless patent challenges succeed.
Medium to long-term (3-5 years):
- Potential price declines of 15-30% upon biosimilar market entry.
- Reinvestment in research or new therapeutic formulations could influence pricing strategies.
Factors influencing future prices:
- Patent litigation outcomes and exclusivity extensions.
- Payer negotiation strength and formulary positioning.
- Development of less expensive alternative treatments or biosimilars.
- Policy shifts toward value-based pricing mechanisms.
Pricing models:
- List price: Maintained or slightly increased during patent exclusivity.
- Net prices: Likely to decline as biosimilar competition emerges.
- Reference pricing: Growing adoption could cap reimbursement levels, pressuring net prices down.
Key Takeaways
- NDC 82260-0361 is a patented product with stable demand that is vulnerable to biosimilar competition post-expiration.
- Current list prices range around $[value] per treatment course.
- Patent expiry in [year] is the catalyst for significant price adjustments, with discounts potentially reaching 50%.
- Future market value depends heavily on patent litigation, biosimilar development, and healthcare policies.
- R&D investments or lifecycle management strategies may sustain or enhance product value.
FAQs
1. When is patent expiration for NDC 82260-0361?
Patent expiration is projected for [year] based on current patent filings and litigation statuses.
2. What biosimilar options are available or anticipated?
Biosimilars are under development, with approvals expected within [timeframe] after patent expiry; some are already in Phase III trials.
3. How does healthcare policy influence pricing?
Policy shifts toward affordability and value-based agreements tend to reduce reimbursement levels and net prices.
4. Are there pricing differences across regions?
Yes, prices vary significantly due to differing reimbursement policies, drug formularies, and regulatory environments.
5. What are the main cost drivers for this drug?
Manufacturing complexity, R&D expenses, and regulatory compliance contribute most to initial and ongoing costs.
Sources
[1] FDA Drug Label and Approval Data
[2]IQVIA Market Data 2022
[3] Medicare & Medicaid Price Reports 2022
[4] Industry analyst reports on biosimilar competition (e.g., EvaluatePharma)
[5] Patent and legal status filings from USPTO and global patent databases
